The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory approvals. Key companies Bayer, Carisma Therapeutics, Moderna, Eureka Therapeutics, AstraZeneca, CRISPR Therapeutics, and others are involved in developing anti-GPC3 targeted therapies for the treatment of indications such as HCC, NSCLC, and others, respectively.
LAS VEGAS, July 10, 2025 /PRNewswire/ -- DelveInsight's Anti-GPC3 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Hepatocellular carcinoma (HCC), Non-small cell lung cancer (NSCLC), Gastric cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging anti-GPC3 targeted therapies, market share of individual therapies, and current and forecasted market size from 2020 to 2040, segmented into 7MM.
0 Comentários